Hi Kluck,
There is nothing new about MaxCyte's Flow Electroporation® technologies being used to manufacture Azer-cel, as it is already in use and won't be used to further improve Azer-cel because it has already been used to improve the manufacturing process of Azer-cel.
Here's a link which explains the technology: Our Flow Electroporation Technology | MaxCyte
The analogy is slightly off because it's more of a rental agreement for those machines rather than a supply agreement, but much like water and electricity, the manufacturing facility can't operate to produce Azer-cel without any of them. I would expect Imugene to have taken over the rental (licencing) agreement for the MaxCyte's Flow Electroporation® machines as much as I'd expect them to take over the access to all the other services required to operate the factory.
Here's an article from 2018 (4 years ago) about the signing of the licencing agreement which Imugene has now taken over:
Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement (prnewswire.com)
- Forums
- ASX - By Stock
- IMU
- MaxCyte and Imugene
MaxCyte and Imugene, page-66
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $356.9M |
Open | High | Low | Value | Volume |
4.9¢ | 4.9¢ | 4.8¢ | $328.5K | 6.792M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
45 | 5443565 | 4.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.9¢ | 2171910 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
36 | 4613688 | 0.048 |
36 | 4066646 | 0.047 |
46 | 3070983 | 0.046 |
60 | 6170008 | 0.045 |
11 | 1951364 | 0.044 |
Price($) | Vol. | No. |
---|---|---|
0.049 | 1200533 | 2 |
0.050 | 4130537 | 15 |
0.051 | 6179811 | 13 |
0.052 | 2579418 | 10 |
0.053 | 1158504 | 8 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
IMU (ASX) Chart |